Camurus AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Camurus AB - overview
Location
Lund, -, Sweden
Primary Industry
Pharmaceuticals
About
Camurus AB is a Swedish pharmaceutical company dedicated to developing innovative treatments for severe and chronic diseases, focusing on advanced therapies that meet critical medical needs. Founded in Lund, Sweden, Camurus AB specializes in pharmaceutical innovations. The company has established a strong presence in the global market, particularly in Europe and North America. As of now, there are no known subsidiaries or major pivots in business strategy.
The company was founded by individuals committed to addressing significant health challenges. Camurus is an international pharmaceutical company focused on developing innovative treatments for severe and chronic diseases. Their core products include advanced therapies for opioid dependence, acromegaly, neuroendocrine tumors, and polycystic liver disease, aimed at improving patient outcomes. The offerings are designed for healthcare providers, hospitals, and specialty clinics, with availability in Europe, North America, and selected regions in Asia.
The company is deeply engaged in research and development to expand its product pipeline. In 2022, Camurus generated a revenue of USD 94. 86 mn with an EBITDA of USD 8. 42 mn.
Revenue is primarily driven by sales of pharmaceutical products through partnerships and direct channels, reflecting their commitment to effective distribution and market standards. Camurus plans to expand its product pipeline with upcoming therapies targeting additional severe and chronic diseases, although specific launch dates are not disclosed. The company aims to penetrate new markets, particularly within Asia and further regions in North America, by 2024. Recent funding will support these initiatives, enabling investment in research and development for new product entries and enhancing market access.
Primary Industry
Pharmaceuticals
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.camurus.com
Total Amount Raised
Subscriber access only
Camurus AB - timeline of key events
Camurus AB - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 46,729,000 | 60,292,000 | 197,620,000 | 207,982,000 | 154,799,000 | 113,737,000 | 54,308,000 | 49,321,000 | 105,605,000 | - | - | - |
| % Revenue Growth (YoY) | - | 29.0% | 227.8% | 5.2% | (25.6%) | (26.5%) | (52.3%) | (9.2%) | 114.1% | - | - | - |
| EBITDA (USD) | (24,909,000) | (16,954,000) | 117,078,000 | 63,602,000 | (200,552,000) | (98,928,000) | (239,436,000) | (282,768,000) | (351,008,000) | - | - | - |
| Operating Income (USD) | (25,461,000) | (17,621,000) | 116,290,000 | 62,199,000 | (204,104,000) | (102,452,000) | (243,524,000) | (287,218,000) | (360,022,000) | - | - | - |
| Operating Margin | (54.5%) | (29.2%) | 58.8% | 29.9% | (131.9%) | (90.1%) | (448.4%) | (582.3%) | (340.9%) | - | - | - |
| % EBITDA Margin | (53.3%) | (28.1%) | 59.2% | 30.6% | (129.6%) | (87.0%) | (440.9%) | (573.3%) | (332.4%) | - | - | - |
| NET Income (USD) | (18,947,000) | (13,740,000) | 90,748,000 | 34,210,000 | (159,542,000) | (80,993,000) | (190,574,000) | (234,676,000) | (289,885,000) | - | - | - |
| % Net Margin | (40.5%) | (22.8%) | 45.9% | 16.4% | (103.1%) | (71.2%) | (350.9%) | (475.8%) | (274.5%) | - | - | - |
Camurus AB - employee data
Camurus AB - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.